It is hypothesized that rescuing the NKG2D–NKG2DL axis via blocking TGF-β will potentially increase tumor elimination by utilizing NKG2D-mediated tumor recognition, and various cancer therapies targeting the TGF-β are being investigated or are in clinical trials. This evidence concerns the gene TGFB1 and neoplasm.